COMPANY

GEn1E Lifesciences

HQ: Palo Alto, CA source · gen1e.com ↗

Keywords: inflammatory diseases Acute Respiratory Distress Syndrome GEn-1124 Gen1E-1124

Location: Palo Alto, CA · source · Dec 29, 2025

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $5.52M (Form D filed Dec 29, 2025). SEC Form D 0001752886-25-000002 (Dec 29, 2025)
Evidence (1 event)
- Dec 29, 2025 · SEC Form D 0001752886-25-000002
  Name of Issuer: GEN1E LIFESCIENCES INC.; CIK: 1752886; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11887377; Total Amount Sold: 5520803; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Oct 29, 2025 Trial start Phase 1: A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects source ↗
Apr 4, 2023 Trial start Phase 2: A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) source ↗
Jan 7, 2021 Trial start Phase 1: Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124 source ↗

2026-10 (ESTIMATED) · Phase 2 · A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) · NCT05795465

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05795465	A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)	Phase 2	Recruiting	Apr 4, 2023	2026-10 (estimated)
NCT07185113	A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects	Phase 1	Completed	Oct 29, 2025	Nov 4, 2025 (actual)
NCT04728061	Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124	Phase 1	Completed	Jan 7, 2021	Jun 18, 2021 (actual)